Latest research on Capecitabine

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Latest findings

A regimen combining the oral agent Capecitabine with Oxaliplatin (XELOX) was developed for the treatment of colorectal cancer. [source, 2016]
Several economic evaluations of regimens including oral preparations such as Capecitabine and tegafur-uracil have shown that such regimens are more cost effective than regimens comprising only injectable preparations [15, 30–32]. [source, 2016]
In both the FAS and PAS (respectively), Paclitaxel (26% and 25%), Docetaxel (17% and 18%), trastuzumab (14% and 11%), Vinorelbine (12% and 11%), and Capecitabine (9% and 11%) were the most commonly used agents in “non-standard” regimens. [source, 2016]
In patients with colorectal cancer in the FAS and PAS (n=153 and n=71, respectively), 5-Fluorouracil (5-FU) plus Oxaliplatin (14% in both populations), 5-FU plus Irinotecan (13% and 20%), Capecitabine plus Oxaliplatin (12% and 10%), and 5-FU plus Irinotecan plus bevacizumab (9% and 11%) were the most common “standard” regimens. [source, 2016]
In conclusion, the miRNA profile predictive for sensitivity to Cisplatin, Epirubicine and Capecitabine was shown to be independently associated with OS and DSS in patients with gastrooesophageal cancer. [source, 2016]
In the available cohort, eight specimens that were treated with S-1 and Capecitabine, a similar fluoropyrimidine agent, were evaluated for potential biomarkers with formalin-fixed paraffin-embedded (FFPE) primary thymic carcinoma specimens (5 core needle biopsy, 2 surgical specimens, and 1 excision biopsy) at diagnosis using PCR quantification of mRNA expression of TS, DPD, OPRT, and TP. [source, 2016]
Also, TP was not unclear to anticipate to be active of Capecitabine. [source, 2016]
Systemic chemotherapies for GEP-NET included Octreotide, VIP (vincristine, Ifosfamide, Cisplatin), XELOX (Capecitabine, Oxaliplatin), EP (Etoposide, Cisplatin), pazopanib, Sunitinib, everolimus, and XELIRI (Capecitabine, Irinotecan). [source, 2016]
It is often used in clinics with other agents, such as 5-flourouracil [33], and Capecitabine [34]. [source, 2016]
Based on growth inhibition of 60 human cancer cell lines (NCI60) subjected to Cisplatin, Epirubicine and Capecitabine, in addition to, baseline miRNA expression of the 60 cell lines, a miRNA-based response predictor to the three chemotherapeutic agents was developed. [source, 2016]